Skin Cancer

Interleukin-2 Pathway Agonist Bempegaldesleukin Plus Nivolumab in the First-Line Treatment of Metastatic Melanoma

In the phase II cohort of a phase I/II trial (PIVOT-02) reported in the Journal of Clinical Oncology, Adi Diab, MD, and colleagues found that the combination...

Hematologic Malignancies
Symptom Management

Ruxolitinib for Glucocorticoid-Refractory or -Dependent Chronic Graft-vs-Host Disease After Allogeneic Stem Cell Transplantation

In the phase III REACH3 trial, reported in The New England Journal of MedicineRobert Zeiser, MD, and colleagues found that ruxolitinib...

Gynecologic Cancers

Bevacizumab in Advanced Ovarian Cancer: Phase III Trial Finds More Is Not Better

In advanced ovarian cancer, the duration of maintenance bevacizumab should remain 15 months, according to the European multicenter...

Breast Cancer

Is There a Disease-Free Survival Benefit With Adjuvant Celecoxib in HER2-Negative Breast Cancer?

In the phase III REACT trial reported in JAMA OncologyR. Charles Coombes, MD, PhD, and colleagues found no disease-free survival benefit...


ASCO Coronavirus Resources

As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...


Sponsored Content

Solid Tumors
Gastrointestinal Cancer

Vivek Subbiah, MD, on RET Fusion–Positive Cancers: Efficacy of Selpercatinib


Study Examines Barriers to Survivorship Care

Even among a large group of cancer survivors who were mostly insured, college-educated, and had annual incomes above the national average, up to 10% delayed care in the previous 12 months because they simply could not afford out-of-pocket expenses like copays and deductibles. These findings were...


Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...


Ann S. LaCasce, MD, on Hodgkin Lymphoma: PET-Adapted Therapy for Bulky Disease

Gynecologic Cancers

HIPEC With Carboplatin for Platinum-Sensitive Recurrent Ovarian Cancer: Safety and Outcomes

In an MSK Team Ovary–led phase II trial reported in the Journal of Clinical Oncology, Zivanovic et al found that use of hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin during secondary cytoreduction followed by chemotherapy did not improve 24-month progression-free survival in...

Head and Neck Cancer

Transoral Surgery Followed by Lower-Dose Radiation in Patients With HPV-Associated Oropharyngeal Cancer at Intermediate Risk of Recurrence

The phase II E3311 trial offers new information about using reduced-intensity treatment in patients with human papillomavirus (HPV)-associated oropharyngeal cancer who are at intermediate risk of recurrence. These findings were presented by Robert L. Ferris, MD, PhD, and colleagues during the 2021...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Solid Tumors

Carey K. Anders, MD, on Brain Metastases: Integrating Immunotherapy Into Clinical Care

Global Cancer Care

Effect of the COVID-19 Pandemic on Delivery of Oncology Services in India

In a study reported in The Lancet Oncology, Ranganathan et al quantified the enormous impact of the COVID-19 pandemic on delivery of cancer services in India. Study Details The study involved data from 41 cancer centers across the nation. The delivery of oncology services between March 1 and May...


Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...